Compare Stocks

Date Range: 

 MERCK Kommanditgesellschaft auf AktienGenmab A/SCureVacHorizon Therapeutics PublicGenmab A/S
SymbolOTCMKTS:MKGAFOTCMKTS:GNMSFNASDAQ:CVACNASDAQ:HZNPNASDAQ:GMAB
Price Information
Current Price$174.00$381.17$100.40$87.93$37.40
52 Week RangeN/ABuyHoldBuyHold
MarketRank™
Overall Score0.50.60.72.81.4
Analysis Score0.00.01.24.53.2
Community Score2.31.92.33.32.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.01.70.0
Earnings & Valuation Score0.01.30.04.40.6
Analyst Ratings
Consensus RecommendationN/ABuyHoldBuyHold
Consensus Price TargetN/AN/A$58.33$111.36$41.57
% Upside from Price TargetN/AN/A-41.90% downside26.65% upside11.15% upside
Trade Information
Market Cap$22.49 billion$23.51 billion$18.77 billion$19.70 billion$24.53 billion
Beta0.70.83N/A1.150.93
Average Volume4611,255970,1721,849,185588,571
Sales & Book Value
Annual Revenue$18.09 billion$804.57 millionN/A$1.30 billion$804.57 million
Price / Sales1.2429.23N/A15.2030.49
Cashflow$37.02 per share$4.97 per shareN/A$3.96 per share$0.46 per share
Price / Cash4.7076.64N/A22.2280.64
Book Value$155.24 per share$34.13 per shareN/A$11.67 per share$3.24 per share
Price / Book1.1211.17N/A7.5311.54
Profitability
Net Income$1.48 billion$324.68 millionN/A$573.02 million$324.68 million
EPSN/AN/AN/A$1.94$0.51
Trailing P/E Ratio0.005.410.0024.0228.99
Forward P/E RatioN/A20.4568.00
P/E GrowthN/AN/AN/A0.592.91
Net Margins10.92%51.02%N/A43.55%50.99%
Return on Equity (ROE)14.29%34.38%N/A25.66%34.40%
Return on Assets (ROA)5.90%30.65%N/A14.19%30.67%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.26%N/A
Current Ratio1.06%8.64%N/A3.49%8.64%
Quick Ratio0.70%8.64%N/A3.39%8.64%
Ownership Information
Institutional Ownership PercentageN/A0.04%4.32%88.59%6.24%
Insider Ownership PercentageN/AN/AN/A4.30%N/A
Miscellaneous
Employees58,1277815001,395781
Shares Outstanding129.24 million61.69 million186.91 million224.77 million655.87 million
Next Earnings Date5/13/2021 (Estimated)8/11/2021 (Estimated)N/A8/4/2021 (Estimated)8/11/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Leerink Partners Stick to Their Hold Rating for Genmab A/SLeerink Partners Stick to Their Hold Rating for Genmab A/S
investing.com - May 9 at 12:47 PM
Genmab A/S (NASDAQ:GMAB) Today’s Hot StockGenmab A/S (NASDAQ:GMAB) Today’s Hot Stock
stocksregister.com - May 8 at 10:02 AM
Genmab A/S (GMAB) Q1 2021 Earnings Call TranscriptGenmab A/S (GMAB) Q1 2021 Earnings Call Transcript
fool.com - May 7 at 3:07 PM
Genmab A/S (GMAB) CEO Jan van de Winkel on Q1 2021 Results - Earnings Call TranscriptGenmab A/S (GMAB) CEO Jan van de Winkel on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 9:52 PM
Genmab A/S (GMAB.CO)Genmab A/S (GMAB.CO)
ca.finance.yahoo.com - May 6 at 12:01 AM
Genmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading VolumeGenmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume
americanbankingnews.com - May 3 at 12:04 PM
Zacks: Analysts Anticipate Genmab A/S (NASDAQ:GMAB) Will Post Quarterly Sales of $214.90 MillionZacks: Analysts Anticipate Genmab A/S (NASDAQ:GMAB) Will Post Quarterly Sales of $214.90 Million
americanbankingnews.com - May 2 at 1:02 AM
Genmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Zacks Investment ResearchGenmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Zacks Investment Research
marketbeat.com - April 27 at 11:31 PM
Genmab A/S (NASDAQ:GMAB) Given New $37.00 Price Target at Morgan StanleyGenmab A/S (NASDAQ:GMAB) Given New $37.00 Price Target at Morgan Stanley
americanbankingnews.com - April 26 at 10:28 AM
GMAB Nov 2021 35.000 putGMAB Nov 2021 35.000 put
uk.finance.yahoo.com - April 26 at 8:11 AM
Genmab A (GMAB): Price Now Near $36.39; Daily Chart Shows Downtrend on 50 Day BasisGenmab A (GMAB): Price Now Near $36.39; Daily Chart Shows Downtrend on 50 Day Basis
etfdailynews.com - April 22 at 3:22 PM
Deutsche Bank Aktiengesellschaft Begins Coverage on Genmab A/S (NASDAQ:GMAB)Deutsche Bank Aktiengesellschaft Begins Coverage on Genmab A/S (NASDAQ:GMAB)
americanbankingnews.com - April 20 at 8:02 AM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
finance.yahoo.com - April 20 at 6:59 AM
Genmab A/S (NASDAQ:GMAB) Price Target Lowered to $37.00 at Morgan StanleyGenmab A/S (NASDAQ:GMAB) Price Target Lowered to $37.00 at Morgan Stanley
americanbankingnews.com - April 19 at 11:32 AM
Genmab A/S Stock Is Estimated To Be Possible Value TrapGenmab A/S Stock Is Estimated To Be Possible Value Trap
finance.yahoo.com - April 6 at 12:35 PM
Genmabs Tisotumab Vedotin In Metastatic Cervical CancerGenmab's Tisotumab Vedotin In Metastatic Cervical Cancer
seekingalpha.com - March 23 at 10:00 PM
Transactions with shares and linked securities in Genmab A/S made by managerial employees and ...Transactions with shares and linked securities in Genmab A/S made by managerial employees and ...
apnews.com - February 25 at 3:38 PM
Genmab A/S (GMAB) Q4 2020 Earnings Call TranscriptGenmab A/S (GMAB) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 23 at 10:16 PM
Genmab Publishes 2020 Annual ReportGenmab Publishes 2020 Annual Report
finance.yahoo.com - February 23 at 12:14 PM
Genmab announces initiation of share buy-back programGenmab announces initiation of share buy-back program
finance.yahoo.com - February 23 at 12:14 PM
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental MedicinesGenmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
wboc.com - February 22 at 12:48 PM
Genmab A/S: Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with RecurrentGenmab A/S: Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent
bloomberg.com - February 12 at 7:01 PM
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) AmyloidosisGenmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
finance.yahoo.com - January 15 at 2:28 PM
Emergent BioSolutions Sees Its Composite Rating Rise To 97Emergent BioSolutions Sees Its Composite Rating Rise To 97
finance.yahoo.com - January 13 at 2:29 PM
Genmab A-S (spons. ADRs) Stock , GMABGenmab A-S (spons. ADRs) Stock , GMAB
markets.businessinsider.com - January 8 at 10:27 PM
Genmab: An European R&D Behemoth With Long-Term PotentialGenmab: An European R&D Behemoth With Long-Term Potential
seekingalpha.com - December 24 at 10:29 PM
DateCompanyBrokerageAction
11/25/2020Genmab A/SUBS GroupReiterated Rating
8/13/2020Genmab A/SBarclaysReiterated Rating
10/1/2018Genmab A/SHC WainwrightReiterated Rating
5/3/2021CureVacGuggenheimInitiated Coverage
4/26/2021CureVacCredit Suisse GroupInitiated Coverage
11/17/2020CureVacBerenberg BankReiterated Rating
9/8/2020CureVacBank of AmericaInitiated Coverage
9/8/2020CureVacJefferies Financial GroupInitiated Coverage
3/29/2021Horizon Therapeutics PublicMorgan StanleyReiterated Rating
3/24/2021Horizon Therapeutics PublicCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/23/2021Horizon Therapeutics PublicStifel NicolausBoost Price Target
3/17/2021Horizon Therapeutics PublicWolfe ResearchInitiated Coverage
11/3/2020Horizon Therapeutics PublicBMO Capital MarketsBoost Price Target
9/9/2020Horizon Therapeutics PublicJPMorgan Chase & Co.Initiated Coverage
7/22/2020Horizon Therapeutics PublicPiper SandlerBoost Price Target
4/20/2021Genmab A/SDeutsche Bank AktiengesellschaftInitiated Coverage
3/15/2021Genmab A/SDNB MarketsUpgrade
3/3/2021Genmab A/SSVB LeerinkLower Price Target
2/25/2021Genmab A/STruistBoost Price Target
2/24/2021Genmab A/SDanskeUpgrade
1/4/2021Genmab A/SRoyal Bank of CanadaBoost Price Target
10/27/2020Genmab A/SThe Goldman Sachs GroupBoost Price Target
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.